Merus N.V.

Biotechnology • Healthcare • Utrecht, Netherlands • MRUS (NGM)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.

31 30 253 8800 Uppsalalaan 17, Netherlands

Stock Performance (90 Days)

Data through Dec 29, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout - ts2.tech

ts2.tech • Dec 30

Genmab completes acquisition of Merus and delists shares from Nasdaq - Investing.com

Investing.com • Dec 30

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - Business Wire

Business Wire • Dec 12

A/S Genmab Purchases 561,042 Shares of Merus (NASDAQ:MRUS) Stock - MarketBeat

MarketBeat • Dec 30

Merus N.V. (MRUS): A Bull Case Theory - Yahoo Finance

Yahoo Finance • Dec 4

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Merus N.V. had layoffs?

No layoff events have been recorded for Merus N.V. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Merus N.V. have?

Merus N.V. has approximately 260 employees.

What industry is Merus N.V. in?

Merus N.V. operates in the Biotechnology industry, within the Healthcare sector.

Is Merus N.V. a publicly traded company?

Yes, Merus N.V. is publicly traded under the ticker symbol MRUS on the NGM. The company has a market capitalization of approximately $7.03 billion.

Where is Merus N.V. headquartered?

Merus N.V. is headquartered in Utrecht, Netherlands at Uppsalalaan 17, Netherlands.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.